AgaMatrix, Sanofi-aventis Join Hands For Blood Glucose Monitoring Solutions

As per the terms of the agreement, AgaMatrix and sanofi-aventis are expected to co-develop solutions in diabetes management that incorporate AgaMatrix’s WaveSense technology.

AgaMatrix’s proprietary WaveSense technology personalizes each test to provide accuracy by employing a new detection method called dynamic electrochemistry to detect and correct for errors caused by differences in blood samples, manufacturing variations and environmental conditions.

Sanofi-aventis will commercialise through its global diabetes division such integrated solutions for patients with diabetes, along with current Sanofi-aventis insulins and delivery devices.

Eric Petreto, VP of device strategy of sanofi-aventis global diabetes division, said: “In building our Global Diabetes Division, our objectives included conducting an exhaustive search for potential partners that have excellent core science, are highly innovative, and have the potential to develop a broad range of products. With AgaMatrix, we’ve found a company that can meet all three objectives in the BGM category.”

Sonny Vu and Sridhar Iyengar, co-founders of AgaMatrix, said: “With Sanofi-aventis’ global presence and sterling reputation, we believe this partnership will enable us to finally fulfill our original vision of making high accuracy blood glucose testing easily available to patients worldwide.”